# A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Source: https://onco.cc/trials/nct06678659/  
OnCo record `nct06678659` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of REC-1245 in non-Hodgkin lymphoma, run by Recursion Pharmaceuticals Inc., now recruiting.

## Summary

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer is a phase 1/2 interventional study registered as NCT06678659 by Recursion Pharmaceuticals Inc., with 170 participants planned, started 2024-11-21 and due to reach its primary completion in 2028-10-30. Interventions recorded: REC-1245.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06678659
- Phase: 1/2
- Setting: A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- Sponsor: Recursion Pharmaceuticals Inc.
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT06678659: https://clinicaltrials.gov/study/NCT06678659

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/)

---
JSON: https://onco.cc/api/v1/entities/nct06678659.json